In this direction, we employed a thorough bioinformatic approach, which in addition to revealing the dysregulation of TGFβ-1 and CXCR4 in various cancers also revealed that TGFβ-1 and CXCR4 when targeted using the respective inhibitors in combination displayed synergy, which is desirable for the better treatment of breast cancer. Here, CXCR4 is linked to breast carcinoma.